For example, in lung and breast cancer, the overexpression of CIP2A resulted in resistance to the EGFR inhibitors lapatinib and erlotinib, while RNA interference-mediated CIP2A depletion sensitized the cells toward these compounds (140, 185). The gene discussed is CIP2A; the disease is breast carcinoma.